California State Teachers Retirement System Grows Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

California State Teachers Retirement System grew its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 18.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 166,337 shares of the company's stock after purchasing an additional 26,363 shares during the period. California State Teachers Retirement System owned about 0.07% of Hims & Hers Health worth $4,022,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in HIMS. Farallon Capital Management LLC grew its stake in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after acquiring an additional 8,364,000 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after buying an additional 4,145,305 shares during the period. Vanguard Group Inc. increased its holdings in shares of Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after acquiring an additional 2,020,722 shares during the period. Yong Rong HK Asset Management Ltd bought a new position in shares of Hims & Hers Health in the 4th quarter worth $41,104,000. Finally, Renaissance Technologies LLC grew its stake in Hims & Hers Health by 29.0% in the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after purchasing an additional 1,562,302 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Insider Activity at Hims & Hers Health

In other news, insider Irene Becklund sold 2,203 shares of the firm's stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total transaction of $63,402.34. Following the completion of the transaction, the insider now directly owns 8,007 shares of the company's stock, valued at $230,441.46. This trade represents a 21.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 11,581 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.22, for a total value of $697,407.82. Following the completion of the sale, the chief financial officer now directly owns 113,816 shares in the company, valued at approximately $6,853,999.52. The trade was a 9.24% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 617,367 shares of company stock valued at $25,227,888. Insiders own 13.71% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Truist Financial dropped their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Needham & Company LLC increased their price target on Hims & Hers Health from $61.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday. Bank of America raised their target price on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a report on Tuesday, April 29th. TD Cowen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $38.00.

Hims & Hers Health Stock Down 1.5%

Shares of NYSE HIMS traded down $0.79 during mid-day trading on Thursday, hitting $52.82. 36,727,389 shares of the company were exchanged, compared to its average volume of 20,502,226. The stock has a 50 day simple moving average of $41.26 and a 200-day simple moving average of $36.68. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The firm has a market cap of $11.82 billion, a price-to-earnings ratio of 120.05 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. During the same period last year, the firm earned $0.05 EPS. The company's quarterly revenue was up 110.7% compared to the same quarter last year. Analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.